We distribute our research widely to institutional and retail investors through various channels, including our proprietary database, website, and other platforms (such as Bloomberg, Thomson Reuters and Factset).
We are fully MiFID II compliant. Our research is paid for by our corporate clients, and we do not carry out any execution business.
Published reports can be obtained by searching our Research Library below, or directly from the relevant Company Pages.
ANGLE
FY21 results: prepared for commercial successFutura Medical
FY21 results reassure on cash runway and hint at EU dealArecor Therapeutics
Ambitious, focussed, and delivering on its promiseScancell
A fresh impetus in delivering immune-oncology vaccinesMaxCyte
Sustained FY21 growth with significantly more potentialAvacta
FY21 results: a year of frustrations and opportunitiesRedx Pharma
RXC008 nominated as GI-ROCK drug candidateFutura Medical
Menarini to commercialise MED3000 in South KoreaMaxCyte
Opening the next chapterHUTCHMED
A genuinely global R&D-driven biopharma business